News

The Computational Approaches for Cancer Workshop at SC20 fosters collaborations and future innovations to better understand, diagnose, treat, and prevent cancer. 

Ruth Nussinov, Ph.D. says her election as a 2020 American Physical Society fellow is an especially gratifying recognition and for a very basic reason: “I am not a physicist.” 

When physicist Stephen Adler, Ph.D., joined the Frederick National Laboratory for Cancer Research (FNL), he quickly observed a gap in the tools to measure radiation doses in preclinical research.  

A cancer patient’s “digital twin” would be the ideal resource for personalized treatment, and creating the technology stands as a grand challenge for the convergence of advanced computing technologies and oncology. 

A digital twin is a computer replica of the systems and processes needed to run simulations without disrupting or harming the real-world object.  

The 2020 Technology Showcase was Maurice Hampton’s second time at the annual event, but his first opportunity to announce a collaboration that wouldn’t have been possible without it.  

A team of researchers at the Frederick National Laboratory for Cancer Research (FNL) has developed a nanotechnology platform which targets the lymphatic system, an approach that could provide more effective treatment and therapies against infectious diseases and cancer. 

The 2020 Technology Showcase on September 9 brought well over 300 viewers for a half-day of presentations and panels on technology commercialization and collaboration. The annual event once again highlighted the capabilities of the Frederick National Laboratory for Cancer Research (FNL), National Cancer Institute (NCI), and greater Frederick region—but this year, with its novel virtual format, it reached a new audience. Attendees logged in from all over the world, including the United Kingdom, Switzerland, Brazil, Malaysia, and China. It was a first for the typically regional event.

By investigating the biological structure of a protein known to cause a genetic skin condition, scientists at the Frederick National Laboratory for Cancer Research validated a decades-old hypothesis about disease implications surrounding the protein’s mutation in a recent study published

Just a few years ago, it was difficult to get any meaningful sequence data from formalin-fixed, paraffin-embedded (FFPE) patient samples.  

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, an initiative that aims to expedite research and development for new medicines, is making headway.